Inventiva is developing lanifibranor, an oral pan-PPAR agonist aimed at treating MASH (metabolic dysfunction-associated steatohepatitis). The drug offers dual metabolic and anti-fibrotic benefits and is seen as complementary to existing treatments like GLP-1 and SGLT2 agents. Inventiva has secured enough funding through mid-2027 and improved governance ahead of the pivotal NATiV3 Phase 3 trial results expected in Q4 2026. Success in this trial could establish lanifibranor as a versatile and differentiated option in the evolving MASH treatment landscape.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
